logo

For the Inventor, By the Inventor

Abingdon, United Kingdom

Oxford Biotherapeutics Ltd

Calculating rank
USPTO Granted Patents = 18

% Expired Patents = 55.6



Forward Citations = 58

Loading Chart...
Loading Chart...

17 inventors (with patents filed for the assignee):

goldMedal Christian Rohlff (14 out of 14 patents)

silverMedal Jonathan Alexander Terrett (11 out of 25 patents)

bronzeMedal Alasdair Stamps (5 out of 6 patents)

4.  Haichun Huang (2 out of 82 patents)

5.  Chin Pan (2 out of 16 patents)

6.  Chetana Rao-Naik (2 out of 13 patents)

7.  James Edward Ackroyd (2 out of 2 patents)

8.  Erika Meaddough (2 out of 2 patents)

9.  Heidi N Leblanc (1 out of 22 patents)

10.  Bingliang Chen (1 out of 13 patents)

11.  Sarah Lee Pogue (1 out of 18 patents)

12.  Michelle Renee Kuhne (1 out of 11 patents)

13.  Rachel L Dusek (1 out of 1 patent)

14.  Arnima Bisht (1 out of 1 patent)

15.  Livija Deban (1 out of 1 patent)


18 patents:

1. 11673963 - CRTAM antibodies and methods of treating cancer (2023-06-13),
2. 10982005 - Antibodies to bone marrow stromal antigen 1 (2021-04-20),
3. 10239956 - Nucleic acid encoding bone marrow stromal antigen 1 antibody (2019-03-26),
4. 10081682 - Conjugated antibodies against LY75 for the treatment of cancer (2018-09-25),
5. 9932411 - Antibodies (2018-04-03),
6. 9903872 - Identification of protein associated with hepatocellular carcinoma, gliobastoma and lung cancer (2018-02-27),
7. 9732160 - Methods of treating acute myeloid leukemia with antibodies to bone marrow stromal antigen 1 (2017-08-15),
8. 9447178 - Therapeutic and diagnostic target (2016-09-20),
9. 9228023 - Anti-ROR1 antibodies and methods of use for treatment of cancer (2016-01-05),
10. 9200055 - Protein (2015-12-01),
11. 9181339 - Antibodies specific to cadherin-17 (2015-11-10),
12. 9175092 - Antibodies to bone marrow stromal antigen 1 (2015-11-03),
13. 8652478 - Method for treating cancer by administering antibody to ephrin type-A receptor 7 (2014-02-18),
14. 8540998 - Methods for treating cancer using ephrin type-A receptor 10 antibodies conjugated to cytotoxic agents (2013-09-24),
15. 8535677 - Antibody drug conjugate treatment of colorectal cancer (2013-09-17),
Company Overview
Oxford Biotherapeutics Ltd, based in Abingdon, GB, is a biotechnology company focused on the development of innovative antibody-drug conjugates and other targeted therapies for cancer treatment. The organization specializes in harnessing its proprietary technology platforms to create novel therapeutics that aim to improve patient outcomes. With a commitment to advancing precision medicine, Oxford Biotherapeutics is dedicated to addressing unmet medical needs in oncology through its cutting-edge research and development efforts.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

18 Patents

#13 in Abingdon

#1,001 in United Kingdom

#34,263 in the World

Abingdon, GB
Abingdon, United Kingdom

Oxford Biotherapeutics Ltd

Forward Citations = 58

17 inventors:

goldMedal Christian Rohlff (14 out of 14 patents)

silverMedal Jonathan Alexander Terrett (11 out of 25 patents)

bronzeMedal Alasdair Stamps (5 out of 6 patents)

4.  Haichun Huang (2 out of 82 patents)

5.  Chin Pan (2 out of 16 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Oxford Biotherapeutics Ltd. Retrieved from https://idiyas.com/company/oxford-biotherapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…